ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
23.008,94
-1,87%
S&P 500
5.770,20
0,55%
Dow Jones
42.801,72
0,52%
Euro vs US Dollar
1,0832
0,00%
Bitcoin
85.946,27
-0,24%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Clearside Biomedical Inc (CLSD)

  7. Clearside Biomedical Inc (CLSD) News

CLSD

Clearside Biomedical (CLSD)

Clearside Biomedical Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CLSD
DatumZeitQuelleÜberschriftSymbolFirma
06/03/202513h05GlobeNewswire Inc.Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMDNASDAQ:CLSDClearside Biomedical Inc
24/02/202523h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLSDClearside Biomedical Inc
21/02/202522h30Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:CLSDClearside Biomedical Inc
20/02/202513h05GlobeNewswire Inc.Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular EdemaNASDAQ:CLSDClearside Biomedical Inc
13/02/202522h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLSDClearside Biomedical Inc
10/02/202513h05GlobeNewswire Inc.Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 MeetingNASDAQ:CLSDClearside Biomedical Inc
04/02/202513h05GlobeNewswire Inc.Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual ConferenceNASDAQ:CLSDClearside Biomedical Inc
28/01/202513h05GlobeNewswire Inc.Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical ProgramNASDAQ:CLSDClearside Biomedical Inc
22/01/202513h05GlobeNewswire Inc.Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and SingaporeNASDAQ:CLSDClearside Biomedical Inc
10/01/202522h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLSDClearside Biomedical Inc
19/12/202413h05GlobeNewswire Inc.Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, EyeNASDAQ:CLSDClearside Biomedical Inc
25/11/202413h05GlobeNewswire Inc.Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United StatesNASDAQ:CLSDClearside Biomedical Inc
12/11/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLSDClearside Biomedical Inc
12/11/202422h05GlobeNewswire Inc.Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLSDClearside Biomedical Inc
07/11/202415h05GlobeNewswire Inc.Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular EdemaNASDAQ:CLSDClearside Biomedical Inc
06/11/202413h05GlobeNewswire Inc.Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceNASDAQ:CLSDClearside Biomedical Inc
04/11/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLSDClearside Biomedical Inc
04/11/202413h05GlobeNewswire Inc.Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of DirectorsNASDAQ:CLSDClearside Biomedical Inc
31/10/202412h05GlobeNewswire Inc.Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024NASDAQ:CLSDClearside Biomedical Inc
22/10/202413h05GlobeNewswire Inc.Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual MeetingNASDAQ:CLSDClearside Biomedical Inc
09/10/202413h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLSDClearside Biomedical Inc
09/10/202412h30GlobeNewswire Inc.Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary OutcomesNASDAQ:CLSDClearside Biomedical Inc
27/08/202413h05GlobeNewswire Inc.Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMDNASDAQ:CLSDClearside Biomedical Inc
12/08/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLSDClearside Biomedical Inc
12/08/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLSDClearside Biomedical Inc
12/08/202422h05GlobeNewswire Inc.Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLSDClearside Biomedical Inc
08/08/202413h05GlobeNewswire Inc.Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:CLSDClearside Biomedical Inc
01/08/202413h05GlobeNewswire Inc.Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024NASDAQ:CLSDClearside Biomedical Inc
29/07/202422h05GlobeNewswire Inc.Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in ChinaNASDAQ:CLSDClearside Biomedical Inc
24/07/202413h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLSDClearside Biomedical Inc
 Showing the most relevant articles for your search:NASDAQ:CLSD

Kürzlich von Ihnen besucht

AMEX
TNA
Direxion Daily Smal Cap ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten